Applied BioMath, LLC Announces Participation at Canines-N-Kids Foundation’s Paws for a Cure Research Symposium

Applied BioMath (, the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation and sponsorship at Canines-N-Kids Foundation's Paws for a Cure Research Symposium occurring November 12-13, 2018 at the Merck Research Laboratories in Boston, MA. 


Lore Gruenbaum, PhD, Executive Director of Biology and Pharmacology at Applied BioMath will participate in the panel discussion "Biopharma challenges: weaving comparative oncology research into development plans" on Tuesday, November 13, 2018 at 2:00pm. In this discussion, panelists will review case studies where canine data has informed clinical trial design and guided go/no-go drug development decisions. Additionally, panelists will provide industry perspectives as to what their needs are, and how they envision receiving canine data that will be useful to complement and inform their preclinical and clinical drug development plans. 


Canines-N-Kids Foundation is a nonprofit committed to promoting the similarity of cancers between children and dogs, funding research for comparative oncology, and collaborating with distinguished researchers to help canines and kids with cancer beat their disease. The Paws for a Cure Research Symposium is a first-of-its-kind meeting that continues the conversation with industry and academic researchers about integrating drug development in pediatric and pet populations to accelerate the discovery of novel and effective treatments for these cancers. 


"We're very excited to sponsor and collaborate with members in the medical research community at the Paws for a Cure Research Symposium," said John Burke, PhD, Co-Founder, President and CEO at Applied BioMath. "Applied BioMath is committed to transforming both the quality and economics of drug invention, and we hope our research will aid in the development of novel medicines that can cure pediatric and pet cancer."


To learn more about the Paws for a Cure Research Symposium, visit


To learn more about the Canines-N-Kids Foundation, visit 


For more information about Applied BioMath's upcoming events, visit 


About Applied BioMath


Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and best path forward into and in the clinic. For more information about Applied BioMath and its services, visit


Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC. 


Press contact:

Kristen Zannella